Arbutus Biopharma appoints Lindsay Androski as CEO

Arbutus Biopharma (ABUS) announced changes to its board of directors and the appointment of Lindsay Androski as CEO. Ms. Androski replaces Michael McElhaugh, the Company’s Interim President and CEO, effective immediately. Ms. Androski will also serve as a member of the Company’s board of directors. Androski is an MIT-trained biologist with nearly 30 years of experience in the areas of biotechnology, law and academia. She has served in a variety of roles at Roivant. She is currently special counsel at Genevant with responsibilities including LNP litigation. In addition to Ms. Androski, four new directors have joined the board: Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija. In connection with the appointment of these new directors, all members of the existing board of directors have stepped down effective immediately and the board was reduced to five members in total. The Company is considering additional directors with expertise in clinical development and may expand the board in the coming months. The Company will temporarily pause participation in investor meetings and conferences while the new board and management team reviews development plans and strategic options for its hepatitis B programs.